The HFSA Virtual AHFTC Board Certification Review 2022 will be comprised of renowned heart failure experts presenting curriculum that has been tailored to the actual ABIM AHFTC examination blueprint. The educational content is rigorous, up-to-date, scientifically fair, and balanced, and meets the needs of heart failure providers who care for patients with heart failure.

The original recording dates were on (August 12-14, 2022).

The HFSA Virtual AHFTC Board Certification Review 2022 is designed for physicians who are preparing to take the ABIM Advanced Heart Failure and Transplant Cardiology Certification Examination or the Maintenance of Certification Assessment Examination, or heart failure specialists seeking an in-depth review in heart failure.

Upon completion of the activity, participants will demonstrate improved competence and ability to:

For the Certification Examination in Advanced Heart Failure and Transplant Cardiology:

1.    Identify gaps in knowledge about advanced heart failure and transplant cardiology
2.    Focus study efforts on filling identified knowledge gaps
3.    Practice for the certification examination with ABIM-style multiple-choice test questions
For Clinical Practice:
1.    Describe the epidemiology of heart failure, including environmental factors, and implement strategies for the prevention of heart failure
2.    Describe the pathophysiology of heart failure, including normal physiology and compensatory and maladaptive mechanisms
3.    Assess and follow the patient with acute or advanced heart failure, using non-invasive and invasive tests and biomarkers
4.    Implement guideline-based therapy for patients with chronic heart failure, including pharmacologic agents; non-pharmacologic options, such as diet and exercise; and implantable devices
5.    Implement appropriate care strategies for patients undergoing chemotherapy or with pulmonary hypertension, heart failure with preserved ejection fraction, or cardiorenal syndrome
6.    Manage comorbidities in patients with chronic heart failure, including sleep disordered breathing, anemia, and depression
7.    Implement strategies for effective disease management of the patient with advanced heart failure, including palliative care and transition to outpatient care
8.    Provide peri-operative management of heart failure patients undergoing cardiac transplantation or implantation of a mechanical circulatory device

Akshay S. Desai, MD, MPH, FHFSA - Brigham and Women’s Hospital, Boston, MA
Maria Rosa Costanzo, MD - Advocate Heart Institute, Naperville, IL                 
Jonathan Rich, MD, FHFSA - Northwestern University Feinberg School of Medicine, Chicago, IL
Nancy Sweitzer, MD, PhD, FHFSA - Washington University School of Medicine, St. Louis, MO

Khadijah Breathett, MD, MS, FHFSA - Indiana University, Indianapolis, IN
Barry A. Borlaug, MD - Mayo Clinic, Rochester, MN
Daniel Burkhoff, MD, PhD - Cardiovascular Research Foundation, New York, NY
Brian Claggett, PhD - Harvard Medical School, Boston, MA
Maria Rosa Costanzo, MD - Advocate Heart Institute, Naperville, IL                  
Jennifer Cowger, MD, MS - Wayne State University, Detroit, MI
Akshay S. Desai, MD, MPH, FHFSA - Brigham and Women’s Hospital, Boston, MA
Mark Drazner, MD, MSc - University of Texas Southwestern Medical Center, Dallas, TX
James Fang, MD, FHFSA - University of Utah, Salt Lake City, UT
Sadiya Khan, MD, MSc - Northwestern University Feinberg School of Medicine, Chicago, IL
Michelle Kittleson, MD, PhD - Cedars Sinai Medical Center, Los Angeles, CA
Eric Krieger, MD - Seattle Children’s Hospital, Seattle, WA
Bonnie Ky, MD, MSCE - University of Philadelphia, Philadelphia, PA
Gregory Lewis, MD - Massachusetts General Hospital, Boston, MA
Jon Lomasney, MD - Northwestern University Feinberg School of Medicine, Chicago, IL
Sean Pinney, MD - University of Chicago, Chicago, IL
Jonathan Rich, MD, FHFSA - Northwestern University Feinberg School of Medicine, Chicago, IL
Joseph Rogers, MD - Texas Heart Institute, Houston, TX
Sanjiv Shah, MD - Northwestern University Feinberg School of Medicine, Chicago, IL
Nancy Sweitzer, MD, PhD, FHFSA - Washington University School of Medicine, St. Louis, MO
Jeffrey Testani, MD, MTR - Yale Heart and Vascular Center, New Haven, CT
Roderick Tung, MD - The University of Chicago Medicine, Chicago, IL
Wendy Tzou, MD - University of Colorado, Aurora, CO
Jane Wilcox, MD, MSc, FHFSA - Northwestern University Feinberg School of Medicine, Chicago, IL

Note: Program also includes the recorded welcoming remarks for each meeting day, live questions and answer segments, and end of day Q&A Faculty Panels.

 

Heart Failure Fundamentals

• Heart Failure Epidemiology and Risk Factors – S. Khan
• Pathophysiology I: Cellular and Energetic Considerations – D. Burkhoff
• Pathophysiology II: Hemodynamic, Structural, and Neurohormonal Considerations – D. Burkhoff
• Diagnosis and Clinical Assessment – M. Drazner
• Cardio-Oncology for the HF boards – B. Ky
• Clinico-Pathologic Correlates in Heart Failure/ Images for the Heart Failure Boards – J. Lomasney
• Statistics for the HF Board – B. Claggett
• Hemodynamics in HF I – J. Fang
• Pulmonary Hypertension - Classification and Initial Evaluation – J. Rich
• Diabetes and COPD – M. Costanzo
• RV Failure and TR Management – B. Borlaug
• Management of Comorbidities in Heart Failure - Sleep Disorders – M. Costanzo

 

Cardiac Transplantation

• Advanced Heart Failure: Defining the Phenotype and Patient Selection for Advanced Therapies – N. Sweitzer
• Immunology: The Basics, PRA, Sensitization, Crossmatch – S. Pinney
• Rejection: Cellular and Antibody Mediated - S. Pinney
• Managing Immunosuppression and Drugs – M. Kittleson
• Heart Transplant, Clinical Outcomes and Complications – M. Kittleson

 

Q&A Faculty Panel I

 

Key Issues in HF Management

• Hemodynamics in HF II – J. Fang
• Optimal Medical Therapy for HFrEF (1) – M. Drazner
• Optimal Medical Therapy for HFrEF (2) – M. Drazner
• HFpEF: Epidemiology, Risk Factors, Diagnosis, Management (for the boards) – S. Shah
• Management of the Hospitalized HF Patient – M. Costanzo
• Pulmonary Hypertension – Therapy – J. Rich
• Management of Common Arrhythmias I - Atrial Fib and Flutter – R. Tung
• Management of Common Arrhythmias II – R. Tung
• Device Therapy in Heart Failure I - Sudden Death Prevention - W. Tzou
• Device Therapy in Heart Failure II – CRT – W. Tzou
• Management of Comorbidities in Heart Failure - Iron Deficiency/Anemia – M. Costanzo
• Cardio Renal Failure Interactions in Heart Failure – J. Testani

 

Specific Heart Failure Syndromes

• Specific Etiologies of HF I: Common Etiologies (CAD, ETOH, Peripartum, Myocarditis) – A. Desai
• Specific Etiologies of HF II: Inherited HF syndromes (including HCM, ARVC, and LVNC) – J. Wilcox
• Specific Etiologies of HF III: Infiltrative Disorders and Restrictive Cardiomyopathy (Amyloidosis, Sarcoidosis, Hemochromatosis, Fabry) – S. Shah

 

Q&A Faculty Panel II

 

Shock/MCS

• Cardiogenic Shock Management – N. Sweitzer
• MCS I: Durable MCS Devices and Outcomes – J. Rogers
• MCS II: Temporary Support Devices and ECMO for the Boards – J. Cowger
• MCS III: MCS Complications and Patient Management – J. Cowger
• MCS IV:  Interactive Shock and Device Management – D. Burkhoff, J. Cowger, J. Rogers, N. Sweitzer

 

Special Topics in HF

• Assessment of Functional Capacity including cardiopulmonary exercise testing – G. Lewis
• Healthcare Disparities in HF - K. Breathett
• Issues in Chronic HF Disease Management (Biomarkers, Remote Monitoring, Lifestyle Interventions) – A. Desai
• Management of Left Sided Valvular Heart Disease in Heart Failure (including functional MR, low gradient AS) – J. Wilcox
• Adult Congenital Heart Disease for the HF Specialist - E. Krieger

 

Q&A Faculty Panel III

Faculty Disclosures:

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:

Khadijah Breathett, MD, MS, FHFSA
Brian Claggett, PhD
Mark Drazner, MD, MSc, FHFSA
Sadiya Khan, MD, MSc
Michelle Kittleson, MD, PHD
Eric Krieger, MD
Jon Lomasney, MD
Jonathan Rich, MD, FHFSA
Joseph Rogers, MD
Sanjiv Shah, MD
Nancy Sweitzer, MD, PhD, FHFSA

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:

Barry A. Borlaug, MD – Consultant: Amgen, Boehringer Ingelheim, Edwards LifeSciences, Merk, Novo Nordisk
Daniel Burkhoff, MD, PhD – Consultant: CardioDyme, ZOLL Medical; Research Support: Abiomed
Maria Rosa Costanzo, MD, FHFSA – Consultant: Nuwellis; Board Member: Nuwellis; Advisory Panel: Boehringer Ingeheim; Research Support: Abbott Laboratories, Novartis, V-Wave
Jennifer Cowger, MD, MS – Research Grant: Abbott Laboratories, Medtronic, Endotronix, Procyrion, Bivacor; Speaker/Honoraria: Abbott, Zoll, Bioventrix; Ownership/Interest: Procyrion; Consultant/Advisory Board: Abbott, Medtronic, Zoll, Endotronix, Procyrion, Bioventrix, Corware, Nuwellis, Bivacor
Akshay S. Desai, MD, MPH, FHFSA – Consultant: Abbott Laboratories, AstraZeneca, BayerAG, Novartis, Cytokinetics, DalCor Pharmaceuticals, GloaxoSmithKline, Merck, Relyspa, Regenron Pharmaceuticals, Verily, Biofourmis, Sun Pharmaceuticals, Lupin Pharmaceuticals, Avidity; Research Support: Abbott Laboratories, AstraZeneca, Bayer AG, Novartis, Alnylam Pharmaceuticals
James C. Fang, MD, FHFSA – Advisory Panel: Novartis, AstraZeneca, Amgen, Abbott Laboratories, ACI Clinical, Windtree Therapeutics, Boehringer Ingelheim
Bonnie Ky, MD, MSCE – Consultant: Pfizer; IIS: Pfizer; Honorarium for Content: Uptodate; Echo Core Lab: Impulse Dynamics
Gregory Lewis, MD – Consultant: NXT
Sean Pinney, MD – Consultant: Abbott Laboratories, CareDX, Medtronic, Procyrion, TransMedics
Jeffrey Testani, MD, MTR – Consultant: 3ive labs, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Astra Zeneca, Novartis, Cardionomic, MagentaMed, Reprieve inc., FIRE1, W.L. Gore, Sanofi, Sequana Medical, Merck, Windtree Therapeutics, Lexicon pharmaceuticals, Precardia, Relypsa, Regeneron; Research Support: 3ive labs, Boehringer Ingelheim, Bristol Myers Squibb, Reprieve inc., FIRE1 Sanofi, Sequana Medical, Otsuka, Abbott, Merck; Stock Shareholder: Reprieve and Sequana
Roderick Tung, MD – Consultant: Boston Scientific, Medtronic, Abbott, Biotronik, Atricure
Wendy Tzou, MD – Consultant: Abbott, Biosense Webster, BioTel (Philips), BioSig, Boston Scientific, Medtronic; Speaker: Abbott, Biosense Webster, Biotronik, BioSig, Boston Scientific, Medtronic; Research: Abbott, Biosense Webster, Boston Scientific, Medtronic; Advisory Board: Biosense Webster, BioTel (Philips), Boston Scientific, Medtronic
Jane Wilcox, MD, MSc, FHFSA – Consultant: Abbott Laboratories; Advisory Panel: Abiomed, Cytokinetics; Speaker’s Bureau: Novartis

Off-Label Disclosure

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this educational activity for a maximum of 23.25 AMA PRA Category 1 Credits™.  
 
The Heart Failure Society of America designates this live activity for a maximum of 23.25 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, which includes participation in the evaluation component and post-test with 75% passing score, enables the participant to earn up to 23.25 MOC points in the Maintenance of Certification (MOC) program. 

Learners  should claim only the credit commensurate with the extent of their participation in the activity.